Fibromyalgia & Chronic Fatigue: A Careful Look at Circulation and EECP

CLAIM 2 — ESTABLISHED

Claim 2 — Circulation and perfusion context in fibromyalgia and chronic fatigue

Fibromyalgia: pain processing is established context; local vascular findings are limited and not diagnostic

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) describes fibromyalgia as a chronic disorder involving pain and tenderness throughout the body, fatigue, and sleep difficulty. Its cause is not fully understood, but the evidence NIAMS summarizes includes increased sensitivity to pain and altered neural-pathway signaling. Those features may also contribute to fatigue, sleep problems, and cognitive symptoms. This is important context: a circulation theory must not replace the established central pain-processing framework or be presented as the cause of fibromyalgia.^[1]

Some research has explored whether local vascular regulation differs in groups with fibromyalgia. For example, a prospective controlled physiologic study measured forearm skin blood flow during local heating in 40 postmenopausal women with fibromyalgia and 20 healthy women. Twenty of the 40 participants with fibromyalgia were included in the post-exercise analysis after completing supervised treadmill walking; the authors reported differences in selected laser-Doppler-derived control signals and responses to local heating, alongside improved pain and fibromyalgia-impact scores after the exercise program.^[6]

That study is not evidence that impaired microcirculation causes fibromyalgia, that its measurements diagnose fibromyalgia, or that improving a peripheral vascular measure improves symptoms. It was a small, selected, single-study physiologic investigation in women; it was not an EECP study, had no EECP comparator or sham, excluded several cardiovascular and metabolic conditions, and involved exercise as a co-intervention. Its findings can reasonably support a research question about local microvascular regulation—not a condition-wide vascular explanation or an EECP recommendation.^[6]

ME/CFS: autonomic and perfusion findings may matter for some people, but are heterogeneous

For ME/CFS, the Centers for Disease Control and Prevention (CDC) notes that some people experience orthostatic intolerance: symptoms can worsen with quiet upright posture and may improve, though not necessarily resolve, when lying down or reclining. The CDC identifies neurally mediated hypotension and postural orthostatic tachycardia syndrome (POTS) as two common forms, while emphasizing that neither is present in every person with ME/CFS and neither condition automatically means a person has ME/CFS.^[4]

A 2025 systematic review examined cerebral-blood-flow (CBF) research across ME/CFS and orthostatic-intolerance literature. It included 118 articles and 9,185 participants overall: 26 articles addressed ME/CFS alone, 81 addressed orthostatic intolerance alone, and 11 addressed both. Twelve articles focused on ME/CFS reported lower CBF than controls, and four of the 11 studies that examined both conditions reported greater reductions when orthostatic intolerance coexisted. The review also found important interpretation limits: unrecognized orthostatic intolerance can confound ME/CFS-only studies, and supine resting measurements may not reflect changes during posture or activity.^[7]

This supports a cautious statement that autonomic regulation and perfusion during upright stress are clinically relevant research domains in some people with ME/CFS. It does not establish a universal CBF abnormality, a diagnostic biomarker, a single cause of fatigue or PEM, or a proof that a therapy which changes cardiovascular hemodynamics will improve ME/CFS symptoms. The review itself notes that CBF measurement is not required for diagnosis and that no diagnostic biomarker is known.^[7]

What the combined label does—and does not—mean

Fibromyalgia and ME/CFS may share symptoms such as fatigue, sleep disturbance, cognitive difficulty, and reduced function, but they are not interchangeable. Chronic fatigue also has many possible causes. A clinician’s assessment, history, examination, and targeted testing may be needed to distinguish fibromyalgia from other conditions; NIAMS notes that there is no single laboratory or imaging test for fibromyalgia and that clinicians generally evaluate for other causes of similar symptoms. This draft does not identify which condition, if any, applies to a reader.^[2]

CLAIM 1 — STRONG

EECP improves circulation through timed counterpulsation

Enhanced external counterpulsation (EECP), also called external counterpulsation (ECP), is a noninvasive, ECG-timed cuff therapy.

EECP is a noninvasive, ECG-timed cardiovascular procedure. Three pairs of pneumatic cuffs around the calves, lower thighs, and upper thighs/buttocks inflate sequentially from distal to proximal at the onset of diastole and release rapidly at the onset of systole. In the cardiovascular physiology described in peer-reviewed literature, this timing produces diastolic pressure augmentation, increases venous return, and contributes to systolic unloading.^[8]

That is a therapy-level circulation mechanism, not a fibromyalgia- or ME/CFS-specific outcome claim. EECP research and clinical programs have principally concerned selected cardiovascular populations, including people with chronic stable or refractory angina and some heart-failure populations. Cleveland Clinic describes EECP as an outpatient treatment for chronic stable angina and notes that care teams review the individual clinical context before treatment. The underlying timing and hemodynamic effects do not demonstrate that EECP treats pain amplification, PEM, sleep disturbance, cognition, fatigue, or function in fibromyalgia or ME/CFS.^[10]

A 2023 systematic review and meta-analysis of 19 randomized controlled trials (1,647 adults) found that adding EECP for 3–7 weeks to usual or conventional care was associated with a higher brachial-artery flow-mediated dilation (FMD) measure than usual/conventional care. The review included adults, largely in cardiovascular or other non-fibromyalgia populations, and reported moderate heterogeneity (I² = 52%). FMD is a vascular surrogate measure; these data do not supply direct evidence about either condition on this page or about their symptoms.^[9]